Log in

Relevant bibliographies by topics / Theraputic use / Journal articles

To see the other types of publications on this topic, follow the link: Theraputic use.

Journal articles on the topic 'Theraputic use'

Author: Grafiati

Published: 4 June 2021

Last updated: 27 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Theraputic use.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Castro, M. Regina. "Thyroid Nodules—Management Dilemmas and Theraputic Considerations." US Endocrinology 00, no. 01 (2005): 1. http://dx.doi.org/10.17925/use.2005.00.01.1f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Castro, M. Regina. "Thyroid Nodules - Management Dilemmas and Theraputic Considerations." US Endocrinology 00, no. 01 (2005): 68. http://dx.doi.org/10.17925/use.2005.00.01.68.

Full text

Abstract:

Thyroid nodules are very common in clinical practice, with an overall prevalence that varies from 4% by palpation to 67% by ultrasonography. The annual incidence by palpation has been estimated at 0.09% by the Framingham study,1which translates into approximately 300,000 new nodules in the US in 2005. Despite their high frequency, only a small fraction (~5%) of thyroid nodules harbor cancer. Because only malignant or large, symptomatic nodules will require surgical excision, a systematic approach to their evaluation is important to avoid unnecessary surgery. Certain aspects in the evaluation a

APA, Harvard, Vancouver, ISO, and other styles

3

Guancial, Elizabeth A., Vinay S. Mahajan, Ronald P. McCaffrey, and Neal Lindeman. "Theraputic Monoclonal Antibody Interference In Immunofixation Electrophoresis." Blood 116, no. 21 (November 19, 2010): 4996. http://dx.doi.org/10.1182/blood.v116.21.4996.4996.

Full text

Abstract:

Abstract Abstract 4996 The application of monoclonal antibodies represents an increasingly powerful weapon in the arsenal against hematologic diseases. With the advent of new therapies come previously unrecognized laboratory interference that if not properly identified could have clinical repercussions. We encountered two patients, neither of whom had a history of plasma cell dyscrasia, who underwent treatment with rituximab for immune thrombocytopenic purpura (ITP) and were discovered to have a monoclonal IgG kappa band on serum protein electrophoresis (SPEP) followed by immunofixation (IFX).

APA, Harvard, Vancouver, ISO, and other styles

4

Neff, Lucas P., Justin M. Allman, and James H. Holmes. "The use of theraputic plasma exchange (TPE) in the setting of refractory burn shock." Burns 36, no. 3 (May 2010): 372–78. http://dx.doi.org/10.1016/j.burns.2009.05.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Poudel, Parashu Ram. "Physics in Medical Science." Himalayan Physics 2 (July 31, 2011): 43–46. http://dx.doi.org/10.3126/hj.v2i2.5210.

Full text

Abstract:

The domain of Physics covers vast area of scientific knowledge. Basic research on assemblies of atomic or nuclear radiation and gyromagnetic moments led to powerful technique for studying molecular structure as well as solid lattices. It led to invention and development of modern medical diagnostic and theraputic tools which have revolutionized the medical practices. Advancement in medical researches as seen today will be well-nigh impossible without the use of the finding of Physics. The funding made on Physics is in fact another way of funding made on human health.Keywords: Radioactivity; Cr

APA, Harvard, Vancouver, ISO, and other styles

6

Mueller, Joseph, Ryan Yao, Kim Selting, Catherine Best-Popescu, Brendan Harley, and Sara Pedron-Haba. "Abstract A045: Engineered systems for tumor modeling facilitate the assessment of theraputic interventions." Cancer Research 84, no. 5_Supplement_1 (March 4, 2024): A045. http://dx.doi.org/10.1158/1538-7445.brain23-a045.

Full text

Abstract:

Abstract Brain cancers remain some of the most challenging tumors to treat. The goal of our research is to use a 3D in vitro model to acquire in-depth understanding of the unique environment of brain tumors in order to find new biomarkers of disease and develop more efficient therapeutic approaches. Glioblastomas (GBM) present a very poor prognosis, they exhibit high infiltration into brain parenchyma, impairing surgical resection and leading to recurrence. The recurrent tumor is predominantly more aggressive and resistant to available therapeutic strategies. Brain extracellular matrix (ECM) p

APA, Harvard, Vancouver, ISO, and other styles

7

Aknouk, Mina, and Kenny Chiu. "S2608 Hemospray, a Novel Theraputic Use to Control Rectal Bleeding in a Case of Refractory Hemorrhagic Radiation Proctitis." American Journal of Gastroenterology 117, no. 10S (October 2022): e1727-e1728. http://dx.doi.org/10.14309/01.ajg.0000867072.17772.0c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Matsumoto, K., H. Kikuchi, S. Kano, H. Iri, H. Takahashi, and M. Umino. "Automated determination of drugs in serum by liquid chromatography with column-switching. I. Separation of antiepileptic drugs and metabolites." Clinical Chemistry 34, no. 1 (January 1, 1988): 141–44. http://dx.doi.org/10.1093/clinchem/34.1.141.

Full text

Abstract:

Abstract This is a fully automated system for determining six common antiepileptic drugs and two principal metabolites of carbamazepine in serum. It is based on "high-performance" liquid chromatography (HPLC), with column switching. TSKprecolumn BSA-ODS and TSKgel ODS-120A (both from Toyo Soda) were used as the precolumn and analytical column, respectively. The former contains octadecylsilyl resins treated with bovine serum albumin (BSA), and does not adsorb macromolecules such as serum proteins but retains small lipophilic molecules such as antiepileptic drugs. Serum samples are directly inje

APA, Harvard, Vancouver, ISO, and other styles

9

Joshi, SN, M. Chaudhary, D. Bhattarai, S. Gnyawali, G. S. Shrestha, and P. Adhikari. "Theraputic application if Poly-2-hydroxy ethyl mathacrylate contact lens in various ocular surface disorders among Nepalese population." Journal of Institute of Medicine Nepal 37, no. 2 (August 30, 2015): 35–39. http://dx.doi.org/10.59779/jiomnepal.713.

Full text

Abstract:

Introduction: Therapeutic contact lens (TCL) is indicated to relieve pain, promote corneal wound healing, provide mechanical protection and support, maintain corneal hydration, improve vision and seal or splint cornea in various ocular surface disorders. Till date no study has been reported about use of contact lenses for these purposes in Nepalese population. is study thus aims to evaluate the outcome of TCL in ocular surface disorders in Nepalese population. Methods: A prospective analysis of patients fitted with TCL for various ocular surface disorders was done at B.P. Koirala Lions centre

APA, Harvard, Vancouver, ISO, and other styles

10

Mentrup, Heather, Anna Ramos, Elizabeth Novak, Steven Ballesteros, Erin Crawford, Meredith Flanagan, and Kevin Mollen. "MITOCHONDRIAL TURNOVER IS ELEVATED IN RESPONSE TO INTESTINAL INFLAMMATION AND IS AMENABLE TO THERAPUTIC TARGETING VIA UROLITHIN A." Inflammatory Bowel Diseases 30, Supplement_1 (January 25, 2024): S3—S4. http://dx.doi.org/10.1093/ibd/izae020.008.

Full text

Abstract:

Abstract Inflammatory bowel disease (IBD) is a complex, multifactorial set of diseases defined by chronic and relapsing inflammation of the gut. Changes in oxidative stress, inflammation, and metabolism are central to the disease process, linking mitochondrial health to IBD pathogenesis. Mitophagy is a quality-control mechanism that selectively removes dysfunctional mitochondria. Multiple mitophagy pathways co-exist in the intestine, including the canonical PINK1/PARKIN pathway and NIX. We have previously shown that NIX is increased in IBD, removing damaged mitochondria in the epithelium. Whet

APA, Harvard, Vancouver, ISO, and other styles

11

Jnaidi, Raneem, António José Almeida, and Lídia M. Gonçalves. "Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Smart Drug Delivery Systems in the Treatment of Glioblastoma Multiforme." Pharmaceutics 12, no. 9 (September 10, 2020): 860. http://dx.doi.org/10.3390/pharmaceutics12090860.

Full text

Abstract:

Glioblastoma multiforme (GBM) is the most common and malignant type of brain tumor. In fact, tumor recurrence usually appears a few months after surgical resection and chemotherapy, mainly due to many factors that make GBM treatment a real challenge, such as tumor location, heterogeneity, presence of the blood-brain barrier (BBB), and others. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) represent the most promising carriers for therapeutics delivery into the central nervous system (CNS) owing to their inherent ability to cross the BBB. In this review, we present th

APA, Harvard, Vancouver, ISO, and other styles

12

Huque, Muhammed Moinul, Ashraf Ul Huq, Kaniz Hasina, and Md Jafrul Hannan. "Role of laparoscopy in the management of impalpable testis in children: Approach in our country." Journal of Paediatric Surgeons of Bangladesh 8, no. 1 (December 9, 2018): 15–19. http://dx.doi.org/10.3329/jpsb.v8i1.69632.

Full text

Abstract:

Introduction: Treatment of the cryptorchid testicle is essential due to the increased risk of infertility and malignancy as well as the risk of testicular trauma and psychological stigma on patients and their parents. Approximately 20% of cryptorchid testicles are impalpable. In these cases, the laparoscopy is the method of choice for both diagnostic and theraputic requirements. Materials and Methods: Between 1, April 2009 to 31, October 2010, 37 testicles of 30 patients were submitted to diagnostic laparoscopy for impalpable testes. This was a prospective study to evaluate the diagnostic accu

APA, Harvard, Vancouver, ISO, and other styles

13

Mishra, Alka, and Vandana Shrivastava. "Exploring the Science of Marma - An Ancient Healing Technique: Marma Therapy." Dev Sanskriti Interdisciplinary International Journal 22 (August 4, 2023): 23–37. http://dx.doi.org/10.36018/dsiij.v20i.157.

Full text

Abstract:

Marma Science, an extraordinary gem in the vast treasure of Ayurvedic knowledge, represents the science of specific vital places in the body (Marmas), that are the ‘seats of life’ (Prana - the vital life force). As any injury to these parts may lead to severe pain, disability, loss of function, loss of sensation, or death, therefore, they hold an important place in the science of surgery. The ancient scriptures have strictly prohibited causing any injury to the Marmas. However, recent researches have used Marma stimulation for theraputic benefits, with encouraging outcomes. Looking at these mu

APA, Harvard, Vancouver, ISO, and other styles

14

Alperovich, Michael, Keith M. Blechman, Fares Samra, Richard Shapiro, Deborah M. Axelrod, Mihye Choi, Nolan S. Karp, and Amber Azniv Guth. "Nipple-sparing mastectomy and subareolar biopsy: To freeze or not to freeze?" Journal of Clinical Oncology 30, no. 27_suppl (September 20, 2012): 185. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.185.

Full text

Abstract:

185 Background: Advances in breast cancer screening and treatment have fostered the use of surgical procedures that increasingly optimize cosmetic outcome, while ensuring oncologic safety remains the primary concern of the oncologic surgeon. The role of nipple-sparing mastectomy (NSM) for risk-reducing surgery and breast cancer is evolving. It can be difficult to demonstrate involvement of the nipple-areolar complex (NAC) preoperatively, and and in this report we examine the utility of intraoperative subareolar frozen section (FS). Methods: Records of patients undergoing NSM at the NYU Langone

APA, Harvard, Vancouver, ISO, and other styles

15

Gowda, Chandrika S., Chunhua Song, Sunil Muthusami, Yali Ding, Mansi Sachdev, Kimberly Payne, and Sinisa Dovat. "Restoring Ikaros Function in Leukemia : Casein Kinase II ( CK2) Inhibition Restores Ikaros Tumor Supressor Function and Shows Theraputic Efficacy in Preclinical Models of High Risk Pediatric Leukemia." Blood 124, no. 21 (December 6, 2014): 3712. http://dx.doi.org/10.1182/blood.v124.21.3712.3712.

Full text

Abstract:

Abstract One common feature of high-risk pediatric B-cell acute lymphoblastic leukemia (B-ALL) is impaired function of the Ikaros (IKZF1) tumor suppressor gene. Ikaros encodes a DNA-binding, zinc finger protein that regulates expression of its target genes. Using chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-SEQ) we determined that Ikaros targets multiple genes that regulate cell cycle progression. Functional studies provided evidence that Ikaros acts as a transcriptional repressor of several key cell cycle-promoting genes. We hypothesize that Ikaros’ ability to r

APA, Harvard, Vancouver, ISO, and other styles

16

Khillan, Ratesh, Kamudi Somnay, and Raj Wadgaonkar. "Therapuetic Use of Alum in Radiation Proctitis." American Journal of Gastroenterology 100 (September 2005): S283. http://dx.doi.org/10.14309/00000434-200509001-00758.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Lu, Sydney X., Lucy Willis, Marsinay Smith, David Suh, Christopher King, Johanne Bautista, Melanie Chow, et al. "CEACAM-1 Is Involved in Graft-Versus-Host-Disease in Murine Allogeneic Bone Marrow Transplantation Models." Blood 110, no. 11 (November 16, 2007): 67. http://dx.doi.org/10.1182/blood.v110.11.67.67.

Full text

Abstract:

Abstract Carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM-1) belongs to a family of carcinoembryonic antigen-associated glycoproteins. It is expressed on leukocytes, endothelium, and epithelium. Microarray analysis showed that CEACAM-1 mRNA is increased in the small bowel during gut graft-versus-host-disease (GVHD) after allogeneic bone marrow transplantation (allo-BMT). Using CEACAM-1−/− mice as recipients or sources of donor bone marrow or T cells caused significantly worse GVHD mortality (p<0.05) compared to wildtype (WT) controls. Histopathological analysis of GVHD t

APA, Harvard, Vancouver, ISO, and other styles

18

Thasneem, K. V. Musaina, K. Sreejith, B. Athulnadh, Namitha Maniyan, Cherakkulath C. Neena, and P. P. Muhamed Faris. "SGLT2 Inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease." Journal of Drug Delivery and Therapeutics 10, no. 6 (November 15, 2020): 203–6. http://dx.doi.org/10.22270/jddt.v10i6.4532.

Full text

Abstract:

Sodium Glucose Co-transporter2 inhibitors are one of the latest anti diabetic drugs that are approved by USFDA. It include Dapagliflozin, Canagliflozin , Ipragliflozin,Empagliflozin, Tofogliflozin,and Luscogliflozin. They act by inhibiting tubular reabsorption of glucose in kidney and increasing urinary excretion of glucose. SGLT2 inhibitors reduce the workload of the proximal tubules and improve tubulointerstitial hypoxia, and allow fibroblasts to start normal erythropoietin production, and thereby exhibit renoprotection .These drugs have beneficial role in the reduction of HbA1c, cardiovascu

APA, Harvard, Vancouver, ISO, and other styles

19

Danon, Limor Meoded, Vanessa Bähr, Elad Schiff, Miriam Ortiz, Benno Brinkhaus, and Barbara Stöckigt. "Learning to Establish a Therapeutic Doctor-Patient Communication: German and Israeli Medical Students Experiencing Integrative Medicine’s Skills." Social Science, Humanities and Sustainability Research 2, no. 4 (October 27, 2021): p48. http://dx.doi.org/10.22158/sshsr.v2n4p48.

Full text

Abstract:

The doctors’ clinical time collides with the increasing of the use of telecare technologies in our digital era, reducing the actual doctor-patient interaction and the potential to engage with therapeutic doctor-patient communication. In our qualitative study, we followed a collaborative German-Israeli project that trained medical students to use complementary and integrative medicine (CIM) methods in order to improve doctor-patient communication. Interviews with the participants and participatory observation revealed the ways the mentors taught CIM methods, the meaning of therapuitic doctor-pa

APA, Harvard, Vancouver, ISO, and other styles

20

Antonelli, Massimo, Giorgio Conti, Andrea Belisari, Lucia S. D'Angiolella, Lorenzo Mantovani, Sabato Montella, Patrizio Piacentini, and Marco Ranieri. "The use of dexmedetomidine in intensive care sedation." Farmeconomia. Health economics and therapeutic pathways 14, no. 1S (May 28, 2013): 1–28. http://dx.doi.org/10.7175/fe.v14i1s.674.

Full text

Abstract:

The goals and recommendations for ICU (Intensive Care Unit) patients’ sedation and analgesia should be to have adequately sedated patients who are calm and arousal, so that they can guarantee a proper evaluation and an adequate control of pain. This way, it is also possible to perform their neurological evaluation, preserving intellectual faculties and helping them in actively participating to their care. Dexmedetomidine is a selective alpha-2 receptor agonist, member of theraputical cathegory: “other hypnotics and sedatives” (ATC: N05CM18). Dexmedetomidine is recommended for the sedation of a

APA, Harvard, Vancouver, ISO, and other styles

21

Kalra, Kavita B., Xiangfei Cheng, Marion Womak, Christopher Gocke, Jyoti B. Patel, Vincent C. O. Njar, and Naoko Takebe. "Novel Retinoic Acid Metabolism Blocking Agents (RAMBAs) Induce Differentiation in ATRA Resistant Cell Line: Potential New Theraputics for Acute Promyleocytic Leukemia (APL)." Blood 106, no. 11 (November 16, 2005): 746. http://dx.doi.org/10.1182/blood.v106.11.746.746.

Full text

Abstract:

Abstract All trans retinoic acid (ATRA) has been used in differentiation therapy for APL and other types of cancers. However, the rapid emergence of ATRA resistance due in part to ATRA-induced acceleration of ATRA metabolism limits its use. A novel strategy to overcome the limitation associated with exogenous ATRA therapy has been developed by inhibiting the cytochrome P450-dependent ATRA-4-hydroxylase enzyme responsible for ATRA metabolism. These inhibitors are referred to as RAMBAs. Novel RAMBAs were developed which demonstrated a superior apoptosis, cell growth inhibition, in vivo anti-tumo

APA, Harvard, Vancouver, ISO, and other styles

22

Inklebarger J, James Inklebarger J., Mr Giles Gyer, Nikiforos Galanis, Mr Jimmy Michael, and Dr Ghulam Adel. "Cinchona Bark For The Treatment Of Covid-19 Pnemonia: A Modern Review Of The Potential Anti-Viral Therapuetic Applications Of An Old Treatment." International Journal of Medical Science and Clinical invention 7, no. 05 (May 1, 2020): 4795–801. http://dx.doi.org/10.18535/ijmsci/v7i05.02.

Full text

Abstract:

PURPOSE: The Coronavirus 2019 (COVID-19) pandemic is an international public health emergency. Vaccines, and acute infection drugs are currently unknown, and when available, expense and distribution issues may impede distribution in undeserved areas. The aim of this systematic review was to summarize the evidence regarding cinchona bark (CB) for its potential anti-viral properties against COVID-19  STUDY DESIGN: A current literature and historical text review was conducted, limited to articles having full text or abstracts available in English, using Google Scholar, Pubmed-NCBI, Sc

APA, Harvard, Vancouver, ISO, and other styles

23

Riedell, Peter A., Jamie Brower, Loretta Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Joseph P. McGuirk, Veronika Bachanova, et al. "A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas." Blood 138, Supplement 1 (November 5, 2021): 2512. http://dx.doi.org/10.1182/blood-2021-151971.

Full text

Abstract:

Abstract Introduction Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel), CD19 directed CAR T cells, are effective treatments (tx) for relapsed/refractory (R/R) aggressive B-cell lymphomas (B-NHL). We present a multicenter retrospective study of safety, patterns of use, resource utilization, and efficacy with commercial axi-cel and tisa-cel in 7 US centers that offer both products for R/R B-NHL. Methods Data collection included all patients (pts) who underwent apheresis from 5/1/2018 (when centers had a choice of either axi-cel or tisa-cel) through 7/31/2019, with a data cutoff

APA, Harvard, Vancouver, ISO, and other styles

24

Lalu, Manoj M., Dean A. Fergusson, Wei Cheng, Marc T. Avey, Dale Corbett, Dar Dowlatshahi, Malcolm R. Macleod, et al. "Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis." F1000Research 8 (January 3, 2019): 11. http://dx.doi.org/10.12688/f1000research.15869.1.

Full text

Abstract:

Introduction: Globally, stroke is the second leading cause of death. Despite the burden of illness and death, few acute interventions are available to patients with ischemic stroke. Over 1,000 potential neuroprotective therapeutics have been evaluated in preclinical models. It is important to use robust evidence synthesis methods to appropriately assess which therapies should be translated to the clinical setting for evaluation in human studies. This protocol details planned methods to conduct a systematic review to identify and appraise eligible studies and to use a network meta-analysis to s

APA, Harvard, Vancouver, ISO, and other styles

25

Svoboda, Jakub, Hatcher J. Ballard, Carrie I. Ho, Mitchell E. Hughes, Elise A. Chong, Adam Duca, Sara Prischak, et al. "Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors." Blood 138, Supplement 1 (November 5, 2021): 2445. http://dx.doi.org/10.1182/blood-2021-153122.

Full text

Abstract:

Abstract Background: Patients (pts) with cancer are at higher risk for complications and mortality related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although mRNA vaccines have been granted Food and Drug Administration emergency use authorization (EUA) for prevention of COVID-19, the pivotal trials largely excluded pts with active cancer. Emerging data suggests suboptimal efficacy of these vaccines in pts with hematologic malignancies. There are also theoretical concerns that programmed cell death protein 1 inhibitors (PD-1i) could potentiate vaccine-related ad

APA, Harvard, Vancouver, ISO, and other styles

26

Jones, J. A., J. Flynn, M. Moran, T. Lin, and J. Byrd. "Trends in pneumonia (PNA) hospitalization among patients (pts) with chronic lymphocytic leukemia (CLL)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e20500-e20500. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20500.

Full text

Abstract:

e20500 Background: Despite recent therapeutic advances, PNA remains a significant source of morbidity and mortality among CLL pts. We determined population-level estimates for the incidence and outcome of PNA hospitalizations. We further investigated secular trends in care by comparing cohorts before (1994) and after (2004) the widespread use of multiagent chemoimmunotherapy. Methods: Using data from the U.S. Nationwide Inpatient Sample and ICD-9CM diagnosis codes, we identified all non-governmental hospitalizations of CLL pts for a primary dx of PNA in calendar years 1994 and 2004. Admissions

APA, Harvard, Vancouver, ISO, and other styles

27

Gordeuk, Victor R., Barbara Kroner, Norma Pugh, Jane S. Hankins, Abdullah Kutlar, Allison A. King, Nirmish Shah, Julie Kanter, Jeffrey Glassberg, and Marsha Treadwell. "Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease." Blood 136, Supplement 1 (November 5, 2020): 33. http://dx.doi.org/10.1182/blood-2020-143315.

Full text

Abstract:

Background. Hydroxyurea reduces pain crises, acute chest syndrome and blood transfusions in sickle cell disease (SCD), but potential detrimental effects on fertility and birth outcomes are an impediment to its use. Patient data on the effects of hydroxyurea when taken during conception and pregnancy are scarce. The Sickle Cell Disease Implementation Consortium (SCDIC) is a cooperative research program of eight clinical centers, a data coordinating center, and the National Heart, Lung, and Blood Institute (NHLBI). One of the SCDIC programs is an SCD patient registry including at least 300 parti

APA, Harvard, Vancouver, ISO, and other styles

28

Christopoulos, Georgios, Zachi I. Attia, Peter A. Noseworthy, Timothy G. Call, Wei Ding, Jose F. Leis, Eli Muchtar, et al. "Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL)." Blood 136, Supplement 1 (November 5, 2020): 50–51. http://dx.doi.org/10.1182/blood-2020-142645.

Full text

Abstract:

Background: Clinical factors including previous history of AF, heart failure, hypertension, valvular heart disease, increased age and male gender increase the risk of AF in CLL patients (Shanafelt, Leukemia and Lymphoma 2017). Treatment with Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib has also been associated with an increased risk of AF in CLL. We evaluated the role of artificial intelligence electrocardiography (AI-ECG) in predicting ibrutinib-induced AF (and, for reference, AF unrelated to ibrutinib) in patients with CLL. Methods: We identified two cohorts of CLL patients usi

APA, Harvard, Vancouver, ISO, and other styles

29

Carniti, Cristiana, Chiara Monfrini, Vanessa Aragona, Martina Magni, Cristina Vella, Eugenio Fardella, Riccardo Betta, et al. "Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy." Blood 138, Supplement 1 (November 5, 2021): 3877. http://dx.doi.org/10.1182/blood-2021-152309.

Full text

Abstract:

Abstract Background: CD19-directed CAR-T cell therapy has shown promising efficacy in relapsed/refractory (R/R) B-cell malignancies in clinical trials resulting in the approval and commercialization of two products (tisagenlecleucel/Tisa-cel and axicabtagene ciloleucel/Axi-cel) for R/R diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL). However, relapses occur in 60-65% of patients (pts) and thus a better understanding of the early determinants of response is critical to improve long-term survival in the real-world scenario. Aims of the study: To assess

APA, Harvard, Vancouver, ISO, and other styles

30

Thompson, Meghan C., Lindsey E. Roeker, Catherine C. Coombs, Jeffrey L. Jensen, Manali Kamdar, Alan Skarbnik, John M. Pagel, et al. "Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax." Blood 138, Supplement 1 (November 5, 2021): 2628. http://dx.doi.org/10.1182/blood-2021-150751.

Full text

Abstract:

Abstract Background: Targeted therapies including ibrutinib, acalabrutinib and venetoclax (ven) have fundamentally changed the treatment of patients (pts) with chronic lymphocytic leukemia (CLL) leading to improved outcomes and durable remissions for many pts. However, CLL remains an incurable disease and a subset of pts will ultimately have progressive CLL following treatment with a covalent Bruton's Tyrosine Kinase inhibitor (cBTKi, e.g., ibrutinib, acalabrutinib) and ven. Data on efficacy of therapies for "double exposed" pts (i.e., pts exposed to both a cBTKi and ven) are extremely limited

APA, Harvard, Vancouver, ISO, and other styles

31

Glaspy, John, Tom Tang, Dean Rutty, Xiaoqiang Yan, Igor Bondarenko, and Dmitrii Krasnozhon. "A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 (benefilgrastim) in Women with Breast Cancer Receiving Myelotoxic Chemotherapy." Blood 124, no. 21 (December 6, 2014): 1584. http://dx.doi.org/10.1182/blood.v124.21.1584.1584.

Full text

Abstract:

Abstract Neutropenia is common in patients receiving myelotoxic chemotherapy. Benefilgrastim, an rhG-CSF dimer (rhG-CSF-FC fusion protein), is a once-per-cycle therapy for prophylactic neutrophil support. In this Phase II trial, 230 women with stage I-IV breast cancer are to be treated for 4 chemotherapy cycles with either docetaxel/cyclophosphamide (TC) or doxorubicin/docetaxel/cyclophosphamide (TAC) chemotherapy, with each cycle lasting approximately 21 days. Patients will be randomized to receive either benefilgrastim or pegfilgrastim (Neulasta; 6 mg fixed dose) one day after chemotherapy d

APA, Harvard, Vancouver, ISO, and other styles

32

Kuruvilla, Philip, Juhi Husain, Henry J. Conter, William To-Dang, Margaret Balcewicz, and Stephen Reingold. "Real World Experience of Ibrutinib in an Ethnically Diverse Canadian Community Hospital." Blood 142, Supplement 1 (November 28, 2023): 6549. http://dx.doi.org/10.1182/blood-2023-172977.

Full text

Abstract:

Chronic Lymphocytic Leukemia (CLL) is an indolent lymphoproliferative disorder commonly managed in community centers. Ibrutinib revolutionized the management of patients with CLL (2). Ibrutinib was initially considered an easy to administer, well tolerated oral medication with excellent efficacy. It was the first clinically available Bruton's Tyrosine Kinase (BTK) inhibitor widely used to treat CLL (3). Recently there have been concerns about cardiovascular toxicities leading to the use of alternative BTK inhibitors (5). Where alternative BTK inhibitors are available these toxicity concerns ha

APA, Harvard, Vancouver, ISO, and other styles

33

Diamond, Akiva, Sabarish Ayyappan, Shufen Cao, Nour Tashtish, Kirsten M. Boughan, Brenda W. Cooper, Pingfu Fu, and Paolo F. Caimi. "Development of a Risk Score for Cardiovascular Events in Anthracycline Treated DLBCL Patients." Blood 138, Supplement 1 (November 5, 2021): 2536. http://dx.doi.org/10.1182/blood-2021-153862.

Full text

Abstract:

Abstract Introduction: There is increased risk of congestive heart failure (CHF) following anthracycline-based chemotherapy in patients with Diffuse Large B-cell lymphoma (DLBCL). Other than increased cumulative anthracycline dose, little is known about risk factors for developing CHF and other cardiovascular events (CVE). Methods: We conducted a retrospective analysis of 539 DLBCL patients diagnosed at University Hospitals Seidman Cancer Center between 2002 - 2016. Baseline patient and disease characteristics, patterns of treatment and outcomes after therapy, including response, survival, rel

APA, Harvard, Vancouver, ISO, and other styles

34

Amonoo, Hermioni L., Areej El-Jawahri, Thomas W. LeBlanc, Alison R. Kavanaugh, Jason A. Webb, Lara Traeger, Annemarie D. Jagielo, et al. "Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML)." Blood 136, Supplement 1 (November 5, 2020): 44–45. http://dx.doi.org/10.1182/blood-2020-133857.

Full text

Abstract:

Background: Patients with acute myeloid leukemia (AML) receiving intensive chemotherapy face a life-threatening illness, experience a prolonged, isolating hospitalization, and endure substantial physical and psychological symptoms. Some patients with AML experience traumatic stress as a result of their diagnosis and illness course. As traumatic stress reactions can negatively impact patients' QOL, mood, and clinical outcomes, it is essential to understand the extent of this trauma, its clinical manifestations, and risk factors to inform targeted management strategies. Post-traumatic stress dis

APA, Harvard, Vancouver, ISO, and other styles

35

Saultz, Jennifer N., Kaycee Moshofsky, Andy Kaempf, Guang Fan, Gabrielle Meyers, Rachel J. Cook, Richard T. Maziarz, Peggy Appel, Francisco Tria, and Staci Williamson. "Early Infection after Allogeneic Transplant Increases NRM without Influencing Relapse Rate." Blood 136, Supplement 1 (November 5, 2020): 21. http://dx.doi.org/10.1182/blood-2020-142048.

Full text

Abstract:

Intro: Relapse post allogeneic transplant is the leading cause of early mortality in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Known risk factors of relapse include persistent disease at the time of transplant, use of anti-thymocyte globulin, reduced intensity conditioning, and absence of chronic graft versus host disease (GVHD). Early infection has been reported to increase non-relapse mortality (NRM) while protecting against hematologic disease relapse (Auletta et al., Blood 2016). We sought to determine the influence of patient features and post-transpla

APA, Harvard, Vancouver, ISO, and other styles

36

Masese, Rita V., Dominique Bulgin, Mitchell Knisely, Liliana Preiss, Eleanor Stevenson, Jane S. Hankins, Marsha Treadwell, et al. "Sex Based Differences in Sickle Cell Disease." Blood 136, Supplement 1 (November 5, 2020): 37. http://dx.doi.org/10.1182/blood-2020-140896.

Full text

Abstract:

Introduction Sickle cell disease (SCD) is the most common inherited blood disorders in the United States. The disease predominantly affects African Americans with 1 out of every 365 individuals born with SCD. The disease is characterized by vascular inflammation and vaso-occlusion leading to numerous complications and multi-organ dysfunction. Previous studies have shown women with SCD tend to outlive their male counterparts. Other than the increased life expectancy, sex-based clinical outcome differences in SCD remain largely unknown. To better characterize sex-based differences in SCD, we ass

APA, Harvard, Vancouver, ISO, and other styles

37

Heitzer, Andrew M., Jennifer Longoria, Evadnie Rampersaud, Sara Rashkin, Jeremie H. Estepp, Victoria Okhomina, Winfred Wang, et al. "Fetal Hemoglobin Mediates the Effect of Beta Globin Gene Polymorphisms on Neurocognitive Functioning in Sickle Cell Disease." Blood 136, Supplement 1 (November 5, 2020): 23–24. http://dx.doi.org/10.1182/blood-2020-137065.

Full text

Abstract:

Background: Fetal hemoglobin (HbF) is the most influential modifier of the clinical and hematologic phenotype of sickle cell disease (SCD) and is highly heritable. Low HbF is independently associated with increased white matter changes on brain imaging and poorer performance on neurocognitive measures (Ruffiuex, Child Neuropsychology, 2013). Our previous work has shown that 11 SNPs in three genes (BCL11A, MYB, and β-globin), contribute over 20% of the variance in HbF (Rampersaud, Kang. et al., 2020, under review). Clinically, these HbF-associated SNPs are associated with disease severity and f

APA, Harvard, Vancouver, ISO, and other styles

38

Masese, Rita V., Dominique Bulgin, Liliana Preiss, Mitchell Knisely, Eleanor Stevenson, Jane S. Hankins, Marsha Treadwell, et al. "Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry." Blood 136, Supplement 1 (November 5, 2020): 3. http://dx.doi.org/10.1182/blood-2020-140743.

Full text

Abstract:

Introduction Pregnancy in sickle cell disease (SCD) is associated with an exacerbation of SCD-related complications and an increased risk of maternal complications. The increased risk is partly due to physiologic adaptations in pregnancy, which include increased metabolic demands and a hypercoagulable state. The maternal death rate for SCD is 629 per 100,000 deliveries, compared to 12 per 100,000 deliveries in black women and 6 per 100,000 deliveries in the general population (Raider et al., 2016). Studies on maternal and perinatal outcomes of patients with SCD present inconsistent and conflic

APA, Harvard, Vancouver, ISO, and other styles

39

Wang, Zhiquan, Justin C. Boysen, Huihuang Yan, Charla R. Secreto, Sameer A. Parikh, Saad S. Kenderian, Wei Ding, Esteban Braggio, Susan L. Slager, and Neil E. Kay. "Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia." Blood 136, Supplement 1 (November 5, 2020): 1. http://dx.doi.org/10.1182/blood-2020-140309.

Full text

Abstract:

Introduction: Chronic Lymphocytic Leukemia (CLL) is characterized by the accumulation of mature-appearing malignant lymphocytes (CLL B-cells) in the blood, marrow, lymph nodes, and spleen. Despite improved outcome with the introduction of novel BCR and BCL-2 inhibitors, disease progression is still a therapeutic challenge from either differential responses or acquired drug resistance. Recent studies in CLL reported alterations of the epigenetic landscape as well as mutations of genes encoding key chromatin machineries. These aberrant chromatin structures may provide novel therapeutic targets f

APA, Harvard, Vancouver, ISO, and other styles

40

Hampel, Paul J., Sameer A. Parikh, Timothy G. Call, Mithun Vinod Shah, Nabila Bennani, Aref Al-Kali, Kari G. Rabe, et al. "Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia." Blood 136, Supplement 1 (November 5, 2020): 39–40. http://dx.doi.org/10.1182/blood-2020-134586.

Full text

Abstract:

INTRODUCTION T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy of mature T-cells. Although responses may been seen with initial alemtuzumab-based therapy, relapse is inevitable and relapsed/refractory disease carries a dismal prognosis. T-PLL has shown in vitro sensitivity to venetoclax, and short-lived clinical responses to venetoclax monotherapy (Smith, Blood Advances 2020; Boidol, Blood 2017) or when given in combination with pentostatin (Alfayez, Leukemia & Lymphoma 2020). Given the lack of standard treatment options, we reviewed the outcomes of patients (pts) wit

APA, Harvard, Vancouver, ISO, and other styles

41

Costa, Luciano J., Sandy W. Wong, Arancha Bermúdez, Javier de la Rubia, María-Victoria Mateos, Enrique M. Ocio, Paula Rodríguez-Otero, et al. "First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial." Blood 134, Supplement_1 (November 13, 2019): 143. http://dx.doi.org/10.1182/blood-2019-122895.

Full text

Abstract:

Introduction: BCMA is a tumor necrosis factor (TNF) receptor superfamily transmembrane glycoprotein essential for the maturation and survival of plasma cells. CC-93269 is an asymmetric 2-arm humanized IgG TCE that binds bivalently to BCMA and monovalently to CD3ε in a 2+1 format (Seckinger A, et al. Cancer Cell. 2017;31:396-410). The CC-93269-mediated interaction between T cells and BCMA-expressing myeloma cells induces T cell receptor/CD3 crosslinking leading to T cell activation, and release of proinflammatory cytokines and cytolytic enzymes, resulting in myeloma cell death. In preclinical s

APA, Harvard, Vancouver, ISO, and other styles

42

Abrisqueta, Pau, Juan-Manuel Sancho, Raul Cordoba, Daniel O. Persky, Charalambos Andreadis, Scott F. Huntington, Cecilia Carpio, et al. "Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)." Blood 134, Supplement_1 (November 13, 2019): 4089. http://dx.doi.org/10.1182/blood-2019-125310.

Full text

Abstract:

Background: Cluster of differentiation 47 (CD47), a widely expressed cell-surface ligand,is overexpressed in various malignancies and is correlated with worse outcomes in NHL. Interaction of CD47 and signal regulatory protein-α (SIRPα) delivers an antiphagocytic 'don't eat me' signal to promote tumor cell evasion from macrophages. CC-90002 is a humanized IgG4-PE CD47 antibody that inhibits CD47-SIRPα interaction and enabled phagocytosis across a panel of cancer cell lines (Narla et al. AACR.2017). In addition to high binding affinity, CC-90002 is potentially differentiated from other CD47 immu

APA, Harvard, Vancouver, ISO, and other styles

43

Foster, Matthew C., Philip A. Roehrs, George E. Hucks, Natalie S. Grover, Paul M. Armistead, Katarzyna Jamieson, Faith Brianne Buchanan, et al. "Safety and Antitumor Effects of CD19-Specific Autologous Chimeric Antigen Receptor-Modified T (CAR-T) Cells Expressing the Inducible Caspase 9 Safety Switch (iC9-CAR19 T Cells) in Adult Acute Lymphoblastic Leukemia (ALL)." Blood 136, Supplement 1 (November 5, 2020): 36–37. http://dx.doi.org/10.1182/blood-2020-139051.

Full text

Abstract:

Introduction: CAR-T cells targeting the CD19 antigen are approved to treat children and young adults with relapsed and refractory B-cell ALL, in whom response rates are &gt;80%. Acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) complicate CAR-T therapy in most patients. Though most patients with CRS or ICANS experience toxicities that can be managed with supportive care including corticosteroids and tocilizumab, 46% experience grade 3-4 CRS and 13% experience grade 3 ICANS (Maude SL et al N Engl J Med 2018; 37:439

APA, Harvard, Vancouver, ISO, and other styles

44

Kamdar, Manali, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, et al. "Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study." Blood 138, Supplement 1 (November 5, 2021): 91. http://dx.doi.org/10.1182/blood-2021-147913.

Full text

Abstract:

Abstract Background: Pts with LBCL primary refractory to or relapsed ≤ 12 mo after first-line (1L) therapy may have poor outcomes with SOC, including salvage CT and ASCT, which underscores a critical unmet need. Liso-cel is an autologous CD19-directed, defined composition, 4-1BB CAR T cell product administered at equal target doses of CD8 + and CD4 + CAR + T cells. In the TRANSCEND NHL 001 study (NCT02631044) in pts with R/R LBCL (≥ 2 prior lines of therapy), liso-cel treatment resulted in an ORR of 73% (CR rate, 53%), 2% grade ≥ 3 cytokine release syndrome (CRS), and 10% grade ≥ 3 neurologica

APA, Harvard, Vancouver, ISO, and other styles

45

Zeidan, Amer M., Daniel J. DeAngelo, Jeanne M. Palmer, Christopher S. Seet, Martin S. Tallman, Xin Wei, Ying Fei Li, et al. "A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results." Blood 134, Supplement_1 (November 13, 2019): 1320. http://dx.doi.org/10.1182/blood-2019-125363.

Full text

Abstract:

Background : CD47 is a transmembrane protein ubiquitously expressed in human cells. CD47 is overexpressed in various malignancies and is correlated with negative prognosis in AML and MDS (Chao et al. Curr Opin Immunol.2012; Majeti et al. Cell.2009). Interaction of CD47 with signal-regulatory protein alpha (SIRPα) expressed on macrophages inhibits phagocytosis (Kim et al. Leukemia.2012). CC-90002, a humanized anti-CD47 monoclonal antibody, blocks CD47/SIRPα interactions, thereby enabling macrophage-mediated killing of tumor cells. In preclinical studies, CC-90002 demonstrated antibody-mediated

APA, Harvard, Vancouver, ISO, and other styles

46

Bishop, Michael R., Michael Dickinson, Duncan Purtill, Pere Barba, Armando Santoro, Nada Hamad, Koji Kato, et al. "Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study." Blood 138, Supplement 2 (December 4, 2021): LBA—6—LBA—6. http://dx.doi.org/10.1182/blood-2021-155068.

Full text

Abstract:

Abstract Background: Standard of care (SOC) for second-line (2L) therapy (tx) of relapsed/refractory aggressive B-cell non-Hodgkin lymphomas (R/R aNHL) includes platinum-based chemotherapy (PCT) followed by autologous hematopoietic cell transplantation (aHCT) in responders. Outcomes are poor for patients (pts) with R/R aNHL who experience progression during or within 12 months (mo) of 1L tx. Tisagenlecleucel (tisa-cel) is an autologous chimeric antigen receptor (CAR) T-cell tx targeting CD19 approved for pts with large B-cell lymphoma (LBCL; US) and diffuse LBCL (non-US) after ≥2 lines of tx.

APA, Harvard, Vancouver, ISO, and other styles

47

Connor, John, Fredrick Rappaport, and Ihor S. Sawczuk. "Results with the Use of MVAC in Theraputic and Adjunctive Settings." Journal of Urology 137, no. 6 (June 1987). http://dx.doi.org/10.1016/s0022-5347(17)75812-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Thakur, Santosh Kumar, Sumit Natthani, and Mita Kotecha. "PRIMITIVE THERAPUTIC BIDS OF MEDICINAL PLANT ROHITAKATECOMELLA UNDULATA (SM.) SEEM.: A COMPREHENSIVE APPRAISAL BASED ON CLASSICAL AYURVEDA TEXTS." GLOBAL JOURNAL FOR RESEARCH ANALYSIS, August 15, 2020, 17–20. http://dx.doi.org/10.36106/gjra/5603204.

Full text

Abstract:

The nature made world is graduallyeyeing towards plant based natural system of medicine like Ayurveda. The novel healing approach of Ayurveda founded on evidence based fundamental approaches are gaining interest of the scientific communities globally. There are various interesting therapies are in the ocean of Ayurveda, still looking for scientific exploration in order to serve the people worldwide. The plant Rohitaka botanically identified as Tecomellaundulata Sm. which is commonly distributed in drier part of North-West and western India, is such an example. The present review aimed to analy

APA, Harvard, Vancouver, ISO, and other styles

49

Li, Yimin, Yonglin Yi, Anqi Lin, Peng Luo, and Jian Zhang. "A comparison of the efficacy of antiangiogenic agents combined with chemotherapy for the treatment of non-small cell lung cancer: a network meta-analysis." Cancer Cell International 20, no. 1 (November 10, 2020). http://dx.doi.org/10.1186/s12935-020-01639-4.

Full text

Abstract:

Abstract Objection To explore the effects of combinations of antiangiogenic agents and chemotherapy agents on non-small cell lung cancer (NSCLC) patients and indirectly compare the therapeutic effect of Endostar combined with chemotherapy and bevacizumab combined with chemotherapy on NSCLC. Methods We searched 3 electronic databases: PubMed, Web of Science and the Cochrane Library. The ORRs, HRs and 95% confidence intervals of OS and PFS were used to compare the efficacy of Endostar combined with chemotherapy and bevacizumab combined with chemotherapy. We use the Bayesian network meta-analysis

APA, Harvard, Vancouver, ISO, and other styles

50

Onallah, Hadil, Ronen Hazan, and Ran Nir-Paz. "2142. The use of Pseudomonas aeruginosa Phage PASA16 for non resolving infections." Open Forum Infectious Diseases 10, Supplement_2 (November 27, 2023). http://dx.doi.org/10.1093/ofid/ofad500.1765.

Full text

Abstract:

Abstract Background A growing number of compassionate phage therapy use cases reported in the last decade, with only a limited number of clinical trials conducted and very few unsuccessful clinical trials reported. However, the limited understanding of individual clinical cases and lack of successful published clinical trials provides little evidence on the role of phages in refractory infections. Our objective was to bridge between single cases to early clinical trials and to describe the compassionate use of a single same phage - PASA16 - in sixteen patients with non-resolving Pseudomonas ae

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!